From humanized mice to fully human antibodies: new tools for drug discovery

Biocytogen is a global biotechnology company dedicated to accelerating drug discovery through innovative platforms
About this Event

As the FDA encourages a shift from non-human primates to alternative models, interest in humanized mice for preclinical studies is rapidly growing. Biocytogen is a global biotechnology company dedicated to accelerating drug discovery through innovative platforms, including advanced humanized animal models and a fully human antibody discovery platform. Our humanized mouse models and antibody assets are widely adopted to support preclinical research worldwide.
Parc Cientific de Barcelona invites you to join this insightful presentations from Biocytogen experts, who will highlight the latest advancements in humanized mouse models and fully human antibodies for therapeutic development.
Agenda

09.30 - 09.45 Introduction by Grisha Domakowski, PCB’s Commercialization and Communication Director

09.45 - 10.10 Application of Humanized Mouse Models in Preclinical Research Xiaobo Liu, Ph.D Biocytogen's Business Development Manager

10.10 - 10:30 Introduction to RenBiologics: fully humanized antibodies for 1000+ therapeutic targets across various modalities by Di Fan, Ph.D., Business Development Manager- Licensing

10:30 - 10:45 Q&A

10.45 - 11.30 Coffee networking

About Biocytogen:

Biocytogen is a global biotech company advancing antibody discovery and drug development through innovative technologies. Through its RenBiologics™ sub-brand, Biocytogen drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ fully human antibody sequences for 450+ global partnerships. RenSuper Workstation™, its AI-powered antibody discovery platform, compresses early discovery timelines from years to months. Leveraging its gene-editing expertise, Biocytogen pioneered drug target knock-in humanized models and offers 5,500+ models via BioMice™, along with one-stop pharmacology and custom gene-editing services. BioMice™, along with one-stop pharmacology and custom gene-editing services. BioMice™ has completed 8,600+ global drug evaluation projects.